苏州近岸蛋白质科技股份有限公司2025年年度业绩预告公告

Group 1 - The company forecasts a net profit attributable to shareholders of the parent company for 2025 to be between -85 million yuan and -66 million yuan [2] - The forecasted net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between -84 million yuan and -65 million yuan [3] - The financial data in this performance forecast has not been audited by a registered accountant [4] Group 2 - In the same period last year, the total profit was -54.2183 million yuan, with a net profit attributable to shareholders of the parent company at -54.4163 million yuan, and a net profit after deducting non-recurring gains and losses at -71.7486 million yuan [5] - The earnings per share for the previous year was -0.78 yuan per share [6] Group 3 - The main reasons for the performance changes include an increase in revenue from the main business due to the continuous enrichment of the product line and the development of new business [6] - The company has increased its R&D investment in areas such as RNA drugs, antibody drugs, gene and cell therapy, organoids, and synthetic biology to strengthen its technological advantages [6] - The company has expanded its marketing team and enhanced brand marketing efforts, leading to an increase in sales expenses [6] - A reduction in government subsidies compared to the previous year has been noted, impacting other income [7]